Neoadjuvant gemcitabine and cisplatin: Another step on the path toward improving the outcomes of patients with high-risk, invasive bladder cancer

Authors

  • Matthew E. Nielsen MD

    Corresponding author
    1. The James Buchanan Brady Urological Institute, the Johns Hopkins Medical Institutions, Baltimore, Maryland
    • The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Marburg 143, 600 North Wolfe Street, Baltimore, MD 21287-2101===

    Search for more papers by this author
    • Fax: (410) 955-0833


  • See referenced original article on pages 2471–7, this issue.

Abstract

Until such time as there are data from prospective randomized trials directly comparing neoadjuvant cisplatin and gemcitabine (GC) to neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin, the data presented in the study by Dash et al in this issue of Cancer provide strong support for the consideration of neoadjuvant GC as an effective and well-tolerated component in the armamentarium against high-risk bladder cancer.

Ancillary